Sentences with phrase «cell lymphoma who»

The US FDA has granted Priority Review designation for tisagenlecleucel (Kymriah) for treatment of adult patients with relapsed or refractory diffuse large B - cell lymphoma who are ineligible for, or have relapsed after, ASCT.

The new indication puts Kymriah in direct competition with Gilead Sciences» Yescarta, which was approved by the U.S. Food and Drug Administration in October for treatment of adults with diffuse large B - cell lymphoma who have failed to respond to other treatments.

Not exact matches

Experience with lymphoma patients, who receive a transplant of their own blood or bone cells after radiation to wipe out their cancer, has shown «there's no doubt it helps,» says bone marrow transplant expert Nelson Chao of Duke University in Durham, North Carolina.

The researchers, who were funded by Leukemia & Lymphoma Research and Cancer Research UK, have shown that some cancer cells are able to draw monoclonal antibodies inside themselves, making them invisible to immune cells.

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

The FDA has approved the CAR T - cell therapy axicabtagene ciloleucel (Yescarta) for the treatment of large B - cell lymphomas in adults who have failed or relapsed after two or more prior treatments.

The US Food and Drug Administration (FDA) has granted Priority Review designation for tisagenlecleucel (Kymriah), formerly known as CTL019, for treatment of adult patients with relapsed or refractory diffuse large B - cell lymphoma (DLBCL) who are ineligible for, or have relapsed after, autologous stem cell transplant.

We describe a 66 - year - old man with a long - standing history of squamous cell carcinoma of the head and neck region who developed nodular - sclerosing subtype of classical Hodgkin lymphoma and primary cutaneous CD8 - positive, cytotoxic variant of mycosis fungoides over a 1 - year period of time.

Cancer researcher Carlo Croce, M.D., who worked at Wistar from 1970 to 1988 and held the position of associate director from 1980 to 1988, cloned and characterized the B - Cell lymphoma (BCL2) gene in 1985, defining its role in various lymphomas.

Terry is the mastermind behind the Canine Lymphoma Education Awareness and Research (CLEAR) Foundation, which created and produced My Friend: Changing the Journey, a documentary about canine cancer to which I contributed due to my role as care provider for and owner of my own dog, Cardiff, who has survived two episodes of T - Cell Lymphoma.